M Schwab

Summary

Affiliation: Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology
Country: Germany

Publications

  1. pmc Cohort profile: Greifswald approach to individualized medicine (GANI_MED)
    Hans J Grabe
    Department of Psychiatry and Psychotherapy, University Medicine Greifswald, Ellernholzstraße 1 2, Greifswald 17475, Germany
    J Transl Med 12:144. 2014
  2. pmc DNA methylation is associated with downregulation of the organic cation transporter OCT1 (SLC22A1) in human hepatocellular carcinoma
    Elke Schaeffeler
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Auerbachstrasse 112, 70376 Stuttgart, Germany
    Genome Med 3:82. 2011
  3. ncbi request reprint Organic anion transporters and their implications in pharmacotherapy
    Arian Emami Riedmaier
    Margarete Fischer Bosch Institute of Clinical Pharmacology, 70 376 Stuttgart, Auerbachstr 112, Germany
    Pharmacol Rev 64:421-49. 2012
  4. pmc Prediction of breast cancer by profiling of urinary RNA metabolites using Support Vector Machine-based feature selection
    Carsten Henneges
    Center for Bioinformatics Tübingen ZBIT, Sand 1, D 72076 Tubingen, Germany
    BMC Cancer 9:104. 2009
  5. ncbi request reprint Genetic polymorphisms of the human MDR1 drug transporter
    Matthias Schwab
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Auerbachstrasse 112, D 70376 Stuttgart, Germany
    Annu Rev Pharmacol Toxicol 43:285-307. 2003
  6. ncbi request reprint [Pharmacogenomics: hype or hope?]
    M Schwab
    Dr Margarete Fischer Bosch Institut für Klinische Pharmakologie, Universitatsklinikum Tubingen, Auerbachstrasse 112, 70376 Stuttgart
    Dtsch Med Wochenschr 136:461-7. 2011
  7. ncbi request reprint Azathioprine therapy and adverse drug reactions in patients with inflammatory bowel disease: impact of thiopurine S-methyltransferase polymorphism
    Matthias Schwab
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
    Pharmacogenetics 12:429-36. 2002
  8. ncbi request reprint Using trade names: a risk factor for accidental drug overdose
    Matthias Schwab
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Auerbachstrasse 112, D 70376 Stuttgart, Germany
    Arch Intern Med 162:1065-6. 2002
  9. ncbi request reprint Down syndrome, transient myeloproliferative disorder, and infantile liver fibrosis
    M Schwab
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
    Med Pediatr Oncol 31:159-65. 1998
  10. ncbi request reprint Thioguanine-nucleotides do not predict efficacy of tioguanine in Crohn's disease
    K R Herrlinger
    Department of Gastroenterology, Hepatology and Endocrinology, Robert Bosch Hospital, Stuttgart, Germany
    Aliment Pharmacol Ther 19:1269-76. 2004

Collaborators

Detail Information

Publications114 found, 100 shown here

  1. pmc Cohort profile: Greifswald approach to individualized medicine (GANI_MED)
    Hans J Grabe
    Department of Psychiatry and Psychotherapy, University Medicine Greifswald, Ellernholzstraße 1 2, Greifswald 17475, Germany
    J Transl Med 12:144. 2014
    ..Herein, we describe the implementation of the scientific and clinical infrastructure that allows future translation of findings relevant to Individualized Medicine into clinical practice...
  2. pmc DNA methylation is associated with downregulation of the organic cation transporter OCT1 (SLC22A1) in human hepatocellular carcinoma
    Elke Schaeffeler
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Auerbachstrasse 112, 70376 Stuttgart, Germany
    Genome Med 3:82. 2011
    ..Therefore, we investigated the role of DNA methylation in the transcriptional regulation of the family members SLC22A1/OCT1, SLC22A2/OCT2 and SLC22A3/OCT3 in HCC...
  3. ncbi request reprint Organic anion transporters and their implications in pharmacotherapy
    Arian Emami Riedmaier
    Margarete Fischer Bosch Institute of Clinical Pharmacology, 70 376 Stuttgart, Auerbachstr 112, Germany
    Pharmacol Rev 64:421-49. 2012
    ....
  4. pmc Prediction of breast cancer by profiling of urinary RNA metabolites using Support Vector Machine-based feature selection
    Carsten Henneges
    Center for Bioinformatics Tübingen ZBIT, Sand 1, D 72076 Tubingen, Germany
    BMC Cancer 9:104. 2009
    ....
  5. ncbi request reprint Genetic polymorphisms of the human MDR1 drug transporter
    Matthias Schwab
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Auerbachstrasse 112, D 70376 Stuttgart, Germany
    Annu Rev Pharmacol Toxicol 43:285-307. 2003
    ..Potential implications of MDR1 polymorphisms for drug disposition, drug effects, and disease risk are discussed...
  6. ncbi request reprint [Pharmacogenomics: hype or hope?]
    M Schwab
    Dr Margarete Fischer Bosch Institut für Klinische Pharmakologie, Universitatsklinikum Tubingen, Auerbachstrasse 112, 70376 Stuttgart
    Dtsch Med Wochenschr 136:461-7. 2011
    ..The implementation of pharmacogenomics into clinical practise is a momentous future challenge that requires the establishment of interdisciplinary networks and professional organizations...
  7. ncbi request reprint Azathioprine therapy and adverse drug reactions in patients with inflammatory bowel disease: impact of thiopurine S-methyltransferase polymorphism
    Matthias Schwab
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
    Pharmacogenetics 12:429-36. 2002
    ....
  8. ncbi request reprint Using trade names: a risk factor for accidental drug overdose
    Matthias Schwab
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Auerbachstrasse 112, D 70376 Stuttgart, Germany
    Arch Intern Med 162:1065-6. 2002
    ..This case illustrates that the use of trade names, omitting the international nonproprietary names of the active moiety, carries the risk of serious adverse drug events by overdose...
  9. ncbi request reprint Down syndrome, transient myeloproliferative disorder, and infantile liver fibrosis
    M Schwab
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
    Med Pediatr Oncol 31:159-65. 1998
    ..In neonates, Down syndrome is rarely accompanied by the leukemoid reaction called transient myeloproliferative disorder...
  10. ncbi request reprint Thioguanine-nucleotides do not predict efficacy of tioguanine in Crohn's disease
    K R Herrlinger
    Department of Gastroenterology, Hepatology and Endocrinology, Robert Bosch Hospital, Stuttgart, Germany
    Aliment Pharmacol Ther 19:1269-76. 2004
    ..Tioguanine (thioguanine) therapy results in much higher levels of 6-thioguanine-nucleotide levels when compared with azathioprine or mercaptopurine...
  11. ncbi request reprint Remission maintenance by tioguanine in chronic active Crohn's disease
    K R Herrlinger
    Robert Bosch Hospital, Stuttgart, Germany
    Aliment Pharmacol Ther 17:1459-64. 2003
    ..Tioguanine may offer an alternative for immunosuppression in chronic active Crohn's disease. Recently, we have shown that tioguanine is effective in inducing rapid remission...
  12. ncbi request reprint Selective induction of human hepatic cytochromes P450 2B6 and 3A4 by metamizole
    T Saussele
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
    Clin Pharmacol Ther 82:265-74. 2007
    ..These data warrant further studies to elucidate the drug-interaction potential of metamizole, especially in patients with long-term treatment...
  13. ncbi request reprint High-throughput genotyping of thiopurine S-methyltransferase by denaturing HPLC
    E Schaeffeler
    Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Auerbachstrasse 112, D-70376 Stuttgart, Germany
    Clin Chem 47:548-55. 2001
    ..Additionally, DHPLC allows a simultaneous screening for novel genetic variability in the TPMT gene...
  14. pmc A variant of the SLC10A2 gene encoding the apical sodium-dependent bile acid transporter is a risk factor for gallstone disease
    Olga Renner
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology and University of Tuebingen, Stuttgart, Germany
    PLoS ONE 4:e7321. 2009
    ..In this study the SLC10A2 gene was investigated to identify novel genetic variants and their association with gallstone formation...
  15. ncbi request reprint High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1)
    Mikko Niemi
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
    Pharmacogenetics 14:429-40. 2004
    ..No significant associations were found between OATP-B, MRP2 or MDR1 polymorphisms and the pharmacokinetics of pravastatin. These results suggest that haplotypes are more informative in predicting the OATP-C phenotype than single SNPs...
  16. ncbi request reprint CYP2C19 polymorphism is a major predictor of treatment failure in white patients by use of lansoprazole-based quadruple therapy for eradication of Helicobacter pylori
    Matthias Schwab
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Auerbachstrasse 112, D 70376 Stuttgart, Germany
    Clin Pharmacol Ther 76:201-9. 2004
    ..This study tests the hypothesis that CYP2C19 wild type ( wt/wt ) in white patients is also associated with a higher probability of treatment failure...
  17. pmc Differential effects of clinically used derivatives and metabolites of artemisinin in the activation of constitutive androstane receptor isoforms
    O Burk
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart and University of Tübingen, Germany
    Br J Pharmacol 167:666-81. 2012
    ..Here, we explore the capacity of antimalarial drugs to induce drug metabolism via activation of constitutive androstane receptors (CAR) by ligand binding...
  18. pmc Effects of atorvastatin metabolites on induction of drug-metabolizing enzymes and membrane transporters through human pregnane X receptor
    E Hoffart
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart and University of Tübingen, Tubingen, Germany
    Br J Pharmacol 165:1595-608. 2012
    ..We here investigate whether they exert differential effects on the induction of these genes via activation of pregnane X receptor (PXR) and constitutive androstane receptor (CAR)...
  19. ncbi request reprint ABCB1 single-nucleotide polymorphisms determine tacrolimus response in patients with ulcerative colitis
    K R Herrlinger
    Department of Gastroenterology, Hepatology and Endocrinology, Robert Bosch Hospital, Stuttgart, Germany
    Clin Pharmacol Ther 89:422-8. 2011
    ..We suggest that ABCB1, but not CYP3A5, may predict short-term remission of Tac in steroid-refractory UC...
  20. pmc Genetic variants of Wnt transcription factor TCF-4 (TCF7L2) putative promoter region are associated with small intestinal Crohn's disease
    Maureen J Koslowski
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, University of Tubingen, Stuttgart, Germany
    PLoS ONE 4:e4496. 2009
    ..38, 95% CI 1.03 to1.84, p = 0.02882). The newly identified genetic association of TCF-4 with ileal CD provides evidence that the decrease in Paneth cell alpha-defensins is a primary factor in disease pathogenesis...
  21. ncbi request reprint Association between the C3435T MDR1 gene polymorphism and susceptibility for ulcerative colitis
    Matthias Schwab
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Auerbachstrasse 112, 70376 Stuttgart, Germany
    Gastroenterology 124:26-33. 2003
    ..Because the MDR1 single nucleotide polymorphism C3435T is associated with lower intestinal P-glycoprotein expression, we tested whether this polymorphism predisposes to development of ulcerative colitis...
  22. ncbi request reprint Esomeprazole-induced healing of gastroesophageal reflux disease is unrelated to the genotype of CYP2C19: evidence from clinical and pharmacokinetic data
    Matthias Schwab
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
    Clin Pharmacol Ther 78:627-34. 2005
    ..We tested whether esomeprazole-induced healing of gastroesophageal reflux disease (GERD) is related to CYP2C19 genotype...
  23. ncbi request reprint A polymorphism in the TC21 promoter associates with an unfavorable tamoxifen treatment outcome in breast cancer
    Matjaz Rokavec
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology and Department of Gynecology, Robert Bosch Hospital, Stuttgart, Germany
    Cancer Res 68:9799-808. 2008
    ..35; 95% CI, 1.34-4.14). Our functional and patient-based results suggest that the TC21 -582C>T polymorphism improves prediction of tamoxifen treatment outcome in breast cancer...
  24. ncbi request reprint Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6
    U M Zanger
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
    Pharmacogenetics 11:573-85. 2001
    ..2, in comparison to 2D6.1, whereas only modest Km changes were observed. Taken together, these data provide further insight into the complex mechanisms that govern the highly variable expression and function of CYP2D6...
  25. ncbi request reprint The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells
    M Hitzl
    Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, Germany
    Pharmacogenetics 11:293-8. 2001
    ..Measurement of rhodamine efflux using flow-cytometry from peripheral blood cells allows assessment of genetically determined differences in P-glycoprotein function...
  26. ncbi request reprint Genetic polymorphisms of glutathione S-transferase A1, the major glutathione S-transferase in human liver: consequences for enzyme expression and busulfan conjugation
    Monika Bredschneider
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
    Clin Pharmacol Ther 71:479-87. 2002
    ....
  27. ncbi request reprint CYP2D6 genotyping strategy based on gene copy number determination by TaqMan real-time PCR
    Elke Schaeffeler
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
    Hum Mutat 22:476-85. 2003
    ..The predictability of the new strategy was systematically evaluated. The semiautomatic TaqMan assay allows high sample throughput and will be useful for pharmacogenetic studies and in the clinical setting...
  28. ncbi request reprint Expression polymorphism of the blood-brain barrier component P-glycoprotein (MDR1) in relation to Parkinson's disease
    Taku Furuno
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Auerbachstr 112, 70376 Stuttgart, Germany
    Pharmacogenetics 12:529-34. 2002
    ..In conclusion, MDR1 and other drug transporters represent plausible candidates as Parkinson's disease risk genes. Larger studies are required to confirm this role in the etiology of Parkinson's disease...
  29. ncbi request reprint Pharmacogenomics of tamoxifen therapy
    Hiltrud Brauch
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
    Clin Chem 55:1770-82. 2009
    ..Tamoxifen is a standard endocrine therapy for the prevention and treatment of steroid hormone receptor-positive breast cancer...
  30. ncbi request reprint Three novel thiopurine S-methyltransferase allelic variants (TPMT*20, *21, *22) - association with decreased enzyme function
    Elke Schaeffeler
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
    Hum Mutat 27:976. 2006
    ..In Caucasians the occurrence of these genetic variants appears to be extremely rare since none of these alleles were identified in a randomly selected control population of 1048 individuals...
  31. ncbi request reprint UDP-glucuronosyltransferase (UGT) polymorphisms affect atorvastatin lactonization in vitro and in vivo
    S Riedmaier
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
    Clin Pharmacol Ther 87:65-73. 2010
    ..The potential of UGT genotyping to identify patients who are at increased risk for failure of therapy and/or adverse effects of statins warrants further investigation...
  32. ncbi request reprint The impact of thyroid disease on the regulation, expression, and function of ABCB1 (MDR1/P glycoprotein) and consequences for the disposition of digoxin
    O Burk
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
    Clin Pharmacol Ther 88:685-94. 2010
    ..In conclusion, thyroid abnormalities can exert significant effects on the expression of P-glycoprotein, thereby altering the disposition and action of drugs that are substrates of P-glycoprotein...
  33. ncbi request reprint Activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase I and II enzymes on their concentration levels in plasma
    T E Mürdter
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
    Clin Pharmacol Ther 89:708-17. 2011
    ..For other enzymes tested, carriers of reduced-function CYP2C9 (*2, *3) alleles had lower plasma concentrations of active metabolites (P < 0.004), pointing to the role of additional pathways...
  34. ncbi request reprint Genetic variability of CYP2B6 in populations of African and Asian origin: allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz
    Kathrin Klein
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
    Pharmacogenet Genomics 15:861-73. 2005
    ..17 (T26S, D28G, R29T) appeared to be functionally normal. These data extend the CYP2B6 knowledge base and should be particularly relevant for anti-HIV-therapy with efavirenz...
  35. ncbi request reprint Pharmacogenomics of human liver cytochrome P450 oxidoreductase: multifactorial analysis and impact on microsomal drug oxidation
    Ana M Gomes
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart, Auerbachstrasse 112, 70376 Stuttgart, Germany
    Pharmacogenomics 10:579-99. 2009
    ..We investigated genetic and nongenetic POR variability and its impact on drug-oxidation activities in human liver microsomes...
  36. ncbi request reprint A novel intronic mutation, 2988G>A, with high predictivity for impaired function of cytochrome P450 2D6 in white subjects
    Sebastian Raimundo
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
    Clin Pharmacol Ther 76:128-38. 2004
    ..Their identification is clinically relevant but remains unsatisfactory because of incomplete characterization of the major allele involved, termed CYP2D6*41 (-1584C, R296C, S486T)...
  37. ncbi request reprint Variable expression of P-glycoprotein in the human placenta and its association with mutations of the multidrug resistance 1 gene (MDR1, ABCB1)
    Monika Hitzl
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
    Pharmacogenetics 14:309-18. 2004
    ..Taken together, the MDR1 polymorphisms C3435T and G2677T are associated with altered P-glycoprotein expression in the human placenta, and may have clinical consequences due to genetically determined, variable drug exposure of the fetus...
  38. ncbi request reprint [Therapy of chronic inflammatory bowel diseases with azathioprine, 6-mercaptopurine and 6-thioguanine. Clinico-pharmacologic aspects]
    M Schwab
    Dr Margarete Fischer Bosch Institut für Klinische Pharmakologie, Stuttgart
    Dtsch Med Wochenschr 128:378-85. 2003
  39. ncbi request reprint Effects of aminosalicylates on thiopurine S-methyltransferase activity: an ex vivo study in patients with inflammatory bowel disease
    H Xin
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
    Aliment Pharmacol Ther 21:1105-9. 2005
    ..Thus, during treatment with azathioprine or mercaptopurine, both metabolized by thiopurine S-methyltransferase, sulfasalazine or 5-aminosalicylate could modify the action of azathioprine/mercaptopurine...
  40. ncbi request reprint Telomere length in different tissues of elderly patients
    U Friedrich
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Auerbachstr 112, 70376, Stuttgart, Germany
    Mech Ageing Dev 119:89-99. 2000
    ..Furthermore, our results indicate that TRF measurement in easily accessible tissues such as blood could serve as a surrogate parameter for the relative telomere length in other tissues...
  41. ncbi request reprint Pharmacokinetic considerations in the treatment of inflammatory bowel disease
    M Schwab
    Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
    Clin Pharmacokinet 40:723-51. 2001
    ..No accumulation was observed when it was administered at intervals of 4 or 8 weeks. Methotrexate may reduce the clearance of infliximab from serum...
  42. ncbi request reprint Mutation screening of apical sodium-dependent bile acid transporter (SLC10A2): novel haplotype block including six newly identified variants linked to reduced expression
    Olga Renner
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology and University of Tübingen, Auerbachstr 112, 70376, Stuttgart, Germany
    Hum Genet 125:381-91. 2009
    ..0157). In future studies a single tag SNP selected of this haplotype block will provide reliable genetic testing to investigate systemically the influence of the SLC10A2 haplotype for disease susceptibility and/or drug response...
  43. ncbi request reprint Sensitive quantification of omeprazole and its metabolites in human plasma by liquid chromatography-mass spectrometry
    Ute Hofmann
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Auerbachstrasse 112, D 70376 Stuttgart, Germany
    J Chromatogr B Analyt Technol Biomed Life Sci 831:85-90. 2006
    ..The method was successfully applied to the determination of pharmacokinetic parameters of esomeprazole and the two major metabolites after a single dose and under steady state conditions...
  44. ncbi request reprint A multiplex MALDI-TOF MS approach facilitates genotyping of DNA from formalin-fixed paraffin-embedded tumour specimens
    Heike Horn
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
    Pharmacogenet Genomics 20:598-604. 2010
    ....
  45. pmc A chromosome 8 gene-cluster polymorphism with low human beta-defensin 2 gene copy number predisposes to Crohn disease of the colon
    Klaus Fellermann
    Department of Internal Medicine I, Robert Bosch Hospital, 70376 Stuttgart, Germany
    Am J Hum Genet 79:439-48. 2006
    ..033). In conclusion, a lower HBD-2 gene copy number in the beta-defensin locus predisposes to colonic CD, most likely through diminished beta-defensin expression...
  46. ncbi request reprint Organic Cation Transporters (OCTs, MATEs), In Vitro and In Vivo Evidence for the Importance in Drug Therapy
    Anne T Nies
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Auerbachstrasse 112, 70376, Stuttgart, Germany
    Handb Exp Pharmacol 201:105-67. 2011
    ....
  47. ncbi request reprint MALDI-TOF mass spectrometry for multiplex genotyping of CYP2B6 single-nucleotide polymorphisms
    Julia K Blievernicht
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
    Clin Chem 53:24-33. 2007
    ..Several nonsynonymous and promoter single-nucleotide polymorphisms (SNPs) in the CYP2B6 gene are associated with altered hepatic expression and function, which affect drug plasma concentrations...
  48. ncbi request reprint Highly multiplexed genotyping of thiopurine s-methyltransferase variants using MALD-TOF mass spectrometry: reliable genotyping in different ethnic groups
    Elke Schaeffeler
    Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart, Germany, and University of Tuebingen, Tuebingen, Germany
    Clin Chem 54:1637-47. 2008
    ..To avoid severe hematotoxicity in patients, determination of the TPMT (thiopurine S-methyltransferase) genotype before commencing thiopurine therapy has become accepted...
  49. pmc Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen
    Werner Schroth
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Auerbachstrasse 112, 70376 Stuttgart, Germany
    JAMA 302:1429-36. 2009
    ..The formation of active metabolites is catalyzed by the polymorphic cytochrome P450 2D6 (CYP2D6) enzyme...
  50. ncbi request reprint Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver
    Anne T Nies
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
    Hepatology 50:1227-40. 2009
    ..0001), and four variants in OCT3 (rs2292334, rs2048327, rs1810126, rs3088442) were associated with reduced OCT3 mRNA levels (P = 0.03)...
  51. ncbi request reprint Clinical pharmacokinetics and use of infliximab
    Ulrich Klotz
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
    Clin Pharmacokinet 46:645-60. 2007
    ....
  52. ncbi request reprint The Paneth cell alpha-defensin deficiency of ileal Crohn's disease is linked to Wnt/Tcf-4
    Jan Wehkamp
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology and University of Tübingen, Auerbachstrasse 12, Stuttgart, Germany
    J Immunol 179:3109-18. 2007
    ..This new link established between a human inflammatory bowel disease and the Wnt pathway/Tcf-4 provides a novel mechanism for pathogenesis in patients with ileal CD...
  53. ncbi request reprint Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes
    Werner Schroth
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Auerbachstrasse 112, D 70376 Stuttgart, Germany
    J Clin Oncol 25:5187-93. 2007
    ..We investigated the predictive value of genetic variants of CYP2D6, CYP2C19, and three other cytochrome P450 enzymes for tamoxifen treatment outcome...
  54. ncbi request reprint Aberrant splicing caused by single nucleotide polymorphism c.516G>T [Q172H], a marker of CYP2B6*6, is responsible for decreased expression and activity of CYP2B6 in liver
    Marco H Hofmann
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart, Germany and University of Tübingen, Auerbachstrasse 112, 70376 Stuttgart, Germany
    J Pharmacol Exp Ther 325:284-92. 2008
    ..These results establish the single nucleotide polymorphism 516G>Tasthe causal sequence variation for severely decreased expression and function associated with CYP2B6*6...
  55. ncbi request reprint Interplay of conjugating enzymes with OATP uptake transporters and ABCC/MRP efflux pumps in the elimination of drugs
    Anne T Nies
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart and University of Tübingen, Auerbachstrasse 112, 70376 Stuttgart, Germany
    Expert Opin Drug Metab Toxicol 4:545-68. 2008
    ..Hepatobiliary elimination is a vectorial process involving uptake transporters in the basolateral hepatocyte membrane, possibly Phase I and Phase II metabolizing enzymes, and ATP-dependent efflux pumps in the apical hepatocyte membrane...
  56. ncbi request reprint A predominate role of CYP1A2 for the metabolism of nabumetone to the active metabolite, 6-methoxy-2-naphthylacetic acid, in human liver microsomes
    Miia Turpeinen
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Auerbachstrasse 112, D 70376 Stuttgart, Germany
    Drug Metab Dispos 37:1017-24. 2009
    ..Taken together, these studies indicate that the formation of the active metabolite of nabumetone, 6-MNA, is predominantly catalyzed by CYP1A2 in HLMs with only minor contribution of other P450s...
  57. ncbi request reprint Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation
    Ulrich M Zanger
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Auerbachstr 112, 70376, Stuttgart, Germany
    Anal Bioanal Chem 392:1093-108. 2008
    ..In this review, we provide an up-to-date summary of the functional polymorphisms and aspects of the functional genomics of the major human drug-metabolizing cytochrome P450s, as well as their clinical significance...
  58. ncbi request reprint Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance
    Ulrich M Zanger
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Auerbachstrasse 112, D 70376 Stuttgart, Germany
    Pharmacogenomics 8:743-59. 2007
    ..In this review, we summarize general biomolecular and pharmacological features and present a detailed up-to-date description of genetic polymorphisms, including a discussion of recent clinical applications of CYP2B6 pharmacogenetics...
  59. ncbi request reprint CYP2C19 polymorphism and proton pump inhibitors
    Ulrich Klotz
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Auerbachstr 112, D 70376 Stuttgart, Germany
    Basic Clin Pharmacol Toxicol 95:2-8. 2004
    ..Therefore initial genotyping for this enzyme and higher dosage in extensive metabolizers is likely to improve the clinical efficacy of proton pump inhibitors...
  60. ncbi request reprint Acute effects of pravastatin on cholesterol synthesis are associated with SLCO1B1 (encoding OATP1B1) haplotype *17
    Mikko Niemi
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
    Pharmacogenet Genomics 15:303-9. 2005
    ..The aim was to investigate whether polymorphisms in the SLCO1B1 gene, encoding the hepatic uptake transporter OATP1B1, influence the short-term effects of pravastatin on cholesterol synthesis...
  61. ncbi request reprint Thiopurine S-methyltransferase as a target for drug interactions
    Hua Wen Xin
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Auerbachstrasse 112, D 70376, Stuttgart, Germany
    Eur J Clin Pharmacol 61:395-8. 2005
    ..The present study was undertaken to investigate the possible effects of various agents on thiopurine methyltransferase (TPMT) activity in red blood cells (RBCs) from patients with chronic inflammatory bowel disease (IBD)...
  62. ncbi request reprint Characterisation of cerivastatin as a P-glycoprotein substrate: studies in P-glycoprotein-expressing cell monolayers and mdr1a/b knock-out mice
    Kari T Kivistö
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Auerbachstrasse 112, 70376 Stuttgart, Germany
    Naunyn Schmiedebergs Arch Pharmacol 370:124-30. 2004
    ..As several statins are P-glycoprotein substrates, beneficial as well as adverse effects of the statins might be affected by interindividual differences in P-glycoprotein expression or function caused by, e.g., the MDR1 polymorphism...
  63. ncbi request reprint Lipid-lowering response to statins is affected by CYP3A5 polymorphism
    Kari T Kivistö
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
    Pharmacogenetics 14:523-5. 2004
    ..These findings suggest that CYP3A5 may be a genetic determinant of interindividual differences in response to certain statins...
  64. ncbi request reprint CYP3A5 genotype is associated with diagnosis of hypertension in elderly patients: data from the DEBATE Study
    Kari T Kivistö
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
    Am J Pharmacogenomics 5:191-5. 2005
    ..The aim of this study was to address the presently controversial question of whether cytochrome P450 (CYP) 3A5 polymorphism is associated with hypertension...
  65. ncbi request reprint Clinical aspects of the MDR1 (ABCB1) gene polymorphism
    Michel Eichelbaum
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Auerbachstrasse 112, 70376 Stuttgart, Germany
    Ther Drug Monit 26:180-5. 2004
    ..Clinical studies on the effects of the C3435T polymorphism and drug treatment with cardiac glycosides, the immunosuppressants cyclosporine and tacrolimus, HIV protease inhibitors, and tricyclic antidepressants are discussed...
  66. ncbi request reprint Comprehensive analysis of thiopurine S-methyltransferase phenotype-genotype correlation in a large population of German-Caucasians and identification of novel TPMT variants
    Elke Schaeffeler
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
    Pharmacogenetics 14:407-17. 2004
    ..Thus, the results of this study provide a solid basis to predict TPMT phenotype in a Northern European Caucasian population by molecular diagnostics...
  67. ncbi request reprint Pharmacogenetics of antimalarial drugs: effect on metabolism and transport
    Reinhold Kerb
    Pharmacogenetics, Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
    Lancet Infect Dis 9:760-74. 2009
    ..Variation in the expression of drug-metabolising enzymes and transport proteins affects the pharmacology of antimalarial drugs. Exploration of pharmacogenetics might help to optimise the use of antimalarial drugs...
  68. ncbi request reprint Topical delivery of therapeutic agents in the treatment of inflammatory bowel disease
    Ulrich Klotz
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Auerbachstrasse 112, D 70376 Stuttgart, Germany
    Adv Drug Deliv Rev 57:267-79. 2005
    ..It can be assumed that for any novel therapeutic principle in IBD the approach of topical delivery will be also tried...
  69. ncbi request reprint Sensitive method for the quantification of urinary pyrimidine metabolites in healthy adults by gas chromatography-tandem mass spectrometry
    Ute Hofmann
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Auerbachstrasse 112, D 70376 Stuttgart, Germany
    J Chromatogr B Analyt Technol Biomed Life Sci 791:371-80. 2003
    ..The method was used for investigating the stability of urine samples and the influence of urine collection at different times...
  70. ncbi request reprint Impact of CYP2D6 genotype on adverse effects during treatment with metoprolol: a prospective clinical study
    Richard Fux
    Abteilung Klinische Pharmakologie, Lehrbereich Allgemeinmedizin der Medizinischen Fakultät, and Koordinierungszentrum Klinische Studien, Universitatsklinikum Tubingen, Tubingen, Germany
    Clin Pharmacol Ther 78:378-87. 2005
    ..The adverse effects studied comprised effects related to the central nervous system, cardiovascular effects, and sexual dysfunction...
  71. ncbi request reprint 6-thioguanine--efficacy and safety in chronic active Crohn's disease
    K R Herrlinger
    Robert Bosch Hospital, Stuttgart, Germany
    Aliment Pharmacol Ther 17:503-8. 2003
    ..The direct use of 6-thioguanine may offer a more rapid and safer alternative. We conducted an open prospective study to investigate the efficacy and safety of 6-thioguanine in chronic active Crohn's disease...
  72. pmc NOD2 (CARD15) mutations in Crohn's disease are associated with diminished mucosal alpha-defensin expression
    J Wehkamp
    Department of Internal Medicine I, Robert Bosch Hospital, Stuttgart, Germany
    Gut 53:1658-64. 2004
    ..Paneth cells also express NOD2. To address the hypothesis that the function of NOD2 may affect expression of Paneth cell defensins, we compared their expression levels with respect to NOD2 mutations in Crohn's disease...
  73. pmc MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine
    Siegfried Drescher
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Auerbachstrasse 112, 70376 Stuttgart, Germany
    Br J Clin Pharmacol 53:526-34. 2002
    ..Using fexofenadine, a known P-glycoprotein substrate, the hypothesis was tested whether this polymorphism also affects the disposition of other drugs in humans...
  74. ncbi request reprint Potent mechanism-based inhibition of human CYP2B6 by clopidogrel and ticlopidine
    Tanja Richter
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
    J Pharmacol Exp Ther 308:189-97. 2004
    ..These results suggest the possibility of drug interactions between thienopyridine derivates and drug substrates of CYP2B6 and CYP2C19...
  75. ncbi request reprint Sex is a major determinant of CYP3A4 expression in human liver
    Renzo Wolbold
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Auerbachstrasse 112, D 70376 Stuttgart, Germany
    Hepatology 38:978-88. 2003
    ..John's wort was found. In conclusion, sex, in addition to PXR and drug exposure, is a major factor for CYP3A4 expression in humans, thus explaining many of the previous observations of sex-dependent drug clearance...
  76. ncbi request reprint Discriminative quantification of cytochrome P4502D6 and 2D7/8 pseudogene expression by TaqMan real-time reverse transcriptase polymerase chain reaction
    Karin Endrizzi
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Auerbachstrasse 112, 70376 Stuttgart, Germany
    Anal Biochem 300:121-31. 2002
    ..46, P < 0.0001) but did not depend on CYP2D6 genotype. These data demonstrate genotype-dependent mRNA expression for CYP2D6 and they emphasize the necessity of differentiating between the functional CYP2D6 and the CYP2D pseudogenes...
  77. ncbi request reprint Polymorphism of the DNA repair enzyme XRCC1 is associated with treatment prediction in anthracycline and cyclophosphamide/methotrexate/5-fluorouracil-based chemotherapy of patients with primary invasive breast cancer
    Malgorzata Jaremko
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, University of Tubingen, Stuttgart, Germany
    Pharmacogenet Genomics 17:529-38. 2007
    ..Therefore, we tested the hypothesis of a relationship between event-free survival and genotype distributions of seven polymorphic DNA repair enzymes and four cell cycle regulators...
  78. ncbi request reprint Pulmonary delivery and tissue distribution of aerosolized antisense 2'-O-Methyl RNA containing nanoplexes in the isolated perfused and ventilated rat lung
    M Dong
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart and University of Tuebingen, Germany
    Eur J Pharm Biopharm 81:478-85. 2012
    ..No prominent changes in lung physiology parameters were observed following inhalation, suggesting good local tolerability of OMR-nanoplex formulation...
  79. ncbi request reprint Telomeres in neonates: new insights in fetal hematopoiesis
    U Friedrich
    Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology and Robert Bosch Hospital, Department of Pathology, Robert Bosch Hospital, 70376 Stuttgart, Germany
    Pediatr Res 49:252-6. 2001
    ..The initial decrease in telomere restriction fragment could be caused by ontogeny-related functional alterations of hematopoietic cells or differences in stem cell turnover or the rate of telomere loss per cell division...
  80. ncbi request reprint Sensitive and rapid quantification of busulfan in small plasma volumes by liquid chromatography-electrospray mass spectrometry
    T E Mürdter
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Auerbachstrasse 112, D 70376 Stuttgart, Germany
    Clin Chem 47:1437-42. 2001
    ....
  81. ncbi request reprint Cardiovascular effects of (R)- and (S)-verapamil and racemic verapamil in humans: a placebo-controlled study
    Dagmar Busse
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
    Eur J Clin Pharmacol 62:613-9. 2006
    ....
  82. ncbi request reprint Serum procalcitonin differentiates inflammatory bowel disease and self-limited colitis
    Klaus R Herrlinger
    Department of Internal Medicine I, Robert Bosch Hospital, Stuttgart, Germany
    Inflamm Bowel Dis 10:229-33. 2004
    ..In addition, because standard laboratory inflammatory parameters are poorly correlated with disease activity in IBD, the relation between PCT levels and disease activity was investigated...
  83. ncbi request reprint Thiopurine treatment in inflammatory bowel disease: clinical pharmacology and implication of pharmacogenetically guided dosing
    Alexander Teml
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
    Clin Pharmacokinet 46:187-208. 2007
    ..To improve response rates in thiopurine therapy of IBD, comprehensive analyses including metabolic patterns and genome-wide profiling in patients with azathioprine/mercaptopurine treatment are required to identify novel candidate genes...
  84. ncbi request reprint Inhibition of human CYP2B6 by N,N',N''-triethylenethiophosphoramide is irreversible and mechanism-based
    Tanja Richter
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Auerbachstr 112, 70376 Stuttgart, Germany
    Biochem Pharmacol 69:517-24. 2005
    ..These findings contribute to better understanding of drug interactions with thioTEPA...
  85. ncbi request reprint A novel functional polymorphism in the transforming growth factor-beta2 gene promoter and tumor progression in breast cancer
    Julia Beisner
    Department of Clinical Chemistry, Robert Bosch Hospital, Auerbachstrasse 110, 70376 Stuttgart, Germany
    Cancer Res 66:7554-61. 2006
    ..18; 95% confidence interval, 1.44-18.62). We provide evidence that the TGFB2 -246ins polymorphism leads to enhanced TGF-beta(2) expression levels in vivo and might thereby contribute to tumor progression and development of metastases...
  86. ncbi request reprint A natural CYP2B6 TATA box polymorphism (-82T--> C) leading to enhanced transcription and relocation of the transcriptional start site
    Jörg Zukunft
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
    Mol Pharmacol 67:1772-82. 2005
    ..Furthermore, a detailed interspecies comparison of CYP2B promoters and transcriptional start sites provided novel insights into evolutionary relationships...
  87. ncbi request reprint Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver
    T Lang
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
    Pharmacogenetics 11:399-415. 2001
    ..These data demonstrate that the extensive interindividual variability of CYP2B6 expression and function is not only due to regulatory phenomena, but also caused by a common genetic polymorphism...
  88. ncbi request reprint Association of SGK1 gene polymorphisms with type 2 diabetes
    Matthias Schwab
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
    Cell Physiol Biochem 21:151-60. 2008
    ..032; OR 4.31, 95% CI 1.19-15.58) more frequent in diabetic patients (7.2 %) than in healthy volunteers from Romania (1.8%). The observations support the view that SGK-1 may participate in the pathogenesis of metabolic syndrome...
  89. ncbi request reprint Differences in goblet cell differentiation between Crohn's disease and ulcerative colitis
    Michael Gersemann
    Department of Internal Medicine I, Robert Bosch Hospital, Stuttgart, Germany
    Differentiation 77:84-94. 2009
    ..Conspicuously, inflammation is associated with an enhanced goblet cell differentiation in CD but not in UC, a defect possibly of pathogenic importance...
  90. ncbi request reprint Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group
    Matthias Schwab
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, University of Stuttgart, Stuttgart, Germany
    J Clin Oncol 26:2131-8. 2008
    ....
  91. ncbi request reprint Determination of 6-thioguanosine diphosphate and triphosphate and nucleoside diphosphate kinase activity in erythrocytes: novel targets for thiopurine therapy?
    Susanne Karner
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart and University of Tuebingen, Tuebingen, Germany
    Ther Drug Monit 32:119-28. 2010
    ..The question whether interindividual variability of NDPK activity may explain differences in 6-thioguanosine 5'-phosphates levels has to be investigated in a prospective large-scale study...
  92. ncbi request reprint Mechanisms of clinical resistance to small molecule tyrosine kinase inhibitors targeting oncogenic tyrosine kinases
    Heiko van der Kuip
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
    Am J Pharmacogenomics 5:101-12. 2005
    ..This article reviews the current knowledge of clinical resistance to small molecule inhibitors approved for treatment of cancer patients...
  93. pmc Reduced Paneth cell alpha-defensins in ileal Crohn's disease
    Jan Wehkamp
    Department of Microbiology and Immunology, School of Medicine, University of California, Davis, 95616, USA
    Proc Natl Acad Sci U S A 102:18129-34. 2005
    ..Thus, the specific deficiency of PC defensins that characterizes ileal CD may compromise innate immune defenses of the ileal mucosa and initiate and/or perpetuate this disease...
  94. pmc Expression and localization of the multidrug resistance protein 5 (MRP5/ABCC5), a cellular export pump for cyclic nucleotides, in human heart
    Peter Dazert
    Department of Pharmacology, Peter Holtz Research Center of Pharmacology and Experimental Therapeutics, Ernst Moritz Arndt University, Greifswald, Germany
    Am J Pathol 163:1567-77. 2003
    ..Therefore, MRP5-mediated cellular export may represent a novel, disease-dependent pathway for cGMP removal from cardiac cells...
  95. ncbi request reprint Mutational analysis of the human dihydropyrimidine dehydrogenase gene by denaturing high-performance liquid chromatography
    Joachim Fischer
    Margarete Fischer Bosch Institute of Clinical Pharmacology, D 70376 Stuttgart, Germany
    Genet Test 7:97-105. 2003
    ..Sequence analysis confirmed all base changes detected. This method will be useful in identifying patients at risk for toxicity prior to 5-FU treatment, as well as in the analysis of individual patients with thymine-uraciluria...
  96. ncbi request reprint Impact of the SLCO1B1 polymorphism on the pharmacokinetics and lipid-lowering efficacy of multiple-dose pravastatin
    Michael Igel
    Department of Clinical Pharmacology, University of Bonn, Bonn, Germany
    Clin Pharmacol Ther 79:419-26. 2006
    ..We have investigated whether this polymorphism influences the pharmacokinetics and lipid-lowering efficacy of multiple-dose pravastatin...
  97. ncbi request reprint Frequent co-occurrence of the TATA box mutation associated with Gilbert's syndrome (UGT1A1*28) with other polymorphisms of the UDP-glucuronosyltransferase-1 locus (UGT1A6*2 and UGT1A7*3) in Caucasians and Egyptians
    Christoph Kohle
    Institute of Pharmacology and Toxicology, University of Tubingen, Tubingen, Germany
    Biochem Pharmacol 65:1521-7. 2003
    ..Frequent haplotypes containing several UGT1 allelic variants should be taken into account in studies on the association between diseases, abnormal drug reactions, and UGT1 family polymorphisms...
  98. ncbi request reprint Visual disorders associated with omeprazole and their relation to CYP2C19 polymorphism
    Markus Lutz
    Division of Clinical Pharmacology, University Hospital Tubingen, Germany
    Pharmacogenetics 12:73-5. 2002
    ..Among 29 patients, we found two poor metabolizers (PMs) of CYP2C19. The PM genotype does not appear to be a risk factor for omeprazole-associated visual disorders...
  99. ncbi request reprint A prospective, open-label trial of 6-thioguanine in patients with ulcerative or indeterminate colitis
    Alexander Teml
    Universitatsklinik fur Innere Medizin IV, Abteilung für Gastroenterologie und Hepatologie, Medizinische Universität Wien, Vienna, Austria
    Scand J Gastroenterol 40:1205-13. 2005
    ..The aim of the present study was to evaluate the safety and efficacy of 6-TG in patients with ulcerative colitis (UC) or indeterminate colitis (IC) intolerant or resistant to AZA/6-MP...
  100. ncbi request reprint The pharmacogenetics of methotrexate in inflammatory bowel disease
    Klaus R Herrlinger
    Gastroenterology Unit, University of Oxford, Gibson Laboratories, Radcliffe Infirmary, Oxford, UK
    Pharmacogenet Genomics 15:705-11. 2005
    ..An individual's response to MTX may in part be genetically determined by functional genetic variation in genes encoding these enzymes. We report a pharmacogenetic evaluation of MTX therapy in IBD...